Eikon Therapeutics, Inc. (EIKN) has filed to raise development capital in an IPO of its common stock, according to SEC S-1 registration information. The company is a large biopharma firm developing ...

All websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings ...

Eikon Therapeutics is planning to become the second biotech to go public in 2026 in another sign the public markets are looking increasingly attractive to drug developers. Eikon emerged publicly in ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eikon's leadership team includes ...

Eikon Therapeutics Inc. filed for an initial public offering to help fund its advanced pipeline of cancer drugs. The company plans for its shares to trade on the Nasdaq Global Market under the symbol ...

Eikon Therapeutics filed for an initial public offering. The late-stage clinical biopharmaceutical company didn't disclose in its Friday filing the price or amount of shares it would offer. It intends ...

Jan 9 (Reuters) – Clinical biopharmaceutical company Eikon ‍Therapeutics on Friday filed for an initial public offering ‌in the ‌United States. Eikon Therapeutics is a late-stage clinical ...

Yes, I would like to be contacted by a representative to learn more about Bloomberg's solutions and services. By submitting this information, I agree to the privacy policy and to learn more about ...

With the open-source Dataverse SDK for Python (announced in Public Preview at Microsoft Ignite 2025), you can fully harness the power of Dataverse business data. This toolkit enables advanced ...

A Farmer School of Business professor has been named one of Poets&Quants for Undergrads 50 Best Undergraduate Business Professors for 2025. Since 2019, assistant professor Peter Nguyen has been a ...